Calamos Advisors LLC Makes New $284,000 Investment in Integra LifeSciences Holdings Corporation $IART

Calamos Advisors LLC acquired a new stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,171 shares of the life sciences company’s stock, valued at approximately $284,000.

Other hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth approximately $25,000. Osaic Holdings Inc. raised its stake in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares during the period. GAMMA Investing LLC lifted its holdings in Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after purchasing an additional 3,742 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Integra LifeSciences by 595.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Integra LifeSciences during the fourth quarter worth $124,000. 84.78% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Stock Performance

IART opened at $19.25 on Friday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95. The business has a fifty day simple moving average of $16.91 and a 200 day simple moving average of $13.08. Integra LifeSciences Holdings Corporation has a 1 year low of $8.70 and a 1 year high of $20.26. The company has a market capitalization of $1.50 billion, a PE ratio of -2.98, a price-to-earnings-growth ratio of 1.33 and a beta of 1.22.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million for the quarter, compared to analysts’ expectations of $381.81 million. During the same quarter last year, the business earned $0.41 EPS. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on IART shares. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Truist Financial raised their target price on shares of Integra LifeSciences from $14.00 to $19.00 and gave the stock a “hold” rating in a research note on Thursday. Citigroup reiterated a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. BMO Capital Markets started coverage on shares of Integra LifeSciences in a report on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 price target on the stock. Finally, Wells Fargo & Company raised their price objective on shares of Integra LifeSciences from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of “Reduce” and a consensus price target of $18.33.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.